Abbott Receives FDA Approval for CardioMEMS HERO Device
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy ABT?
Abbott announced the FDA has approved the company's CardioMEMS Hero device - a pulmonary artery pressure reader - to support the care of people living with heart failure. The company said the reader contains new design features to help empower heart failure patients and their clinicians with the daily insights they need to detect and combat heart failure progression. Abbott will soon begin commercial release of the CardioMEMS HERO reader in the United States.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 110.550
Low
136.00
Averages
148.11
High
169.00
Current: 110.550
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott's Phased Retirement Program Gains Popularity
- Growth of Phased Retirement: According to a survey by the Society for Human Resource Management, only 7% of firms offer formal phased retirement programs, yet a growing number of workers are seeking flexible work arrangements to transition gradually into retirement, reflecting their desire for better work-life balance.
- Abbott's 'Freedom to Work' Program: Abbott offers its 'Freedom to Work' program for employees aged 55 and older with over 10 years of service, allowing them to work four days a week or take up to five additional weeks off, which, despite a salary reduction, retains full-time benefits and aids in talent retention.
- Rising Retirement Age: Since the launch of Abbott's phased retirement program in 2008, over 2,100 employees have participated, resulting in an increase in the average retirement age from 58 to 61, demonstrating the company's success in knowledge transfer and talent retention.
- Financial Necessity of Employees: Research indicates that one-third of baby boomers are delaying retirement primarily due to financial necessity, with many workers in their 50s and 60s needing to continue working to meet savings goals while maintaining health insurance coverage, highlighting the urgent demand for phased retirement options.
See More
Mead Johnson Faces Major Litigation Challenge
- Litigation Timeline: Mead Johnson's Enfamil product is facing a bellwether trial in the US Multidistrict Litigation set for July 6, 2026, involving over 775 lawsuits, indicating a growing legal risk for the company.
- Potential Liabilities: Analysts estimate that the total potential liability from infant formula litigation could range from £400 million to £8 billion, which could significantly impact Mead Johnson's financial health and investor confidence.
- Market Share Concerns: With Mead Johnson and Abbott Laboratories holding approximately 80% of the US infant formula market, the litigation poses a substantial risk to their market positions, potentially affecting sales and brand reputation.
- Corporate Accountability: Attorneys emphasize that this trial will provide families an opportunity to seek justice, highlighting the manufacturers' failure to adequately warn about the risks associated with cow's-milk-based formulas, which may lead to stricter industry regulations on product safety.
See More
Dividend Stocks Surge Amid Market Volatility, Outperforming S&P 500
- Dividend Stocks Performance: In 2026, dividend aristocrats are outperforming the broader market, with the ProShares S&P 500 Dividend Aristocrats ETF up 10% year-to-date compared to less than 1% for the S&P 500, reflecting investors' preference for stable income amid market volatility.
- Coca-Cola Dividend Increase: Coca-Cola announced a 4% increase in its quarterly dividend to 53 cents per share in February, marking its 64th consecutive year of dividend growth, and returned $8.8 billion to shareholders last year, demonstrating strong cash flow and market stability.
- NextEra Energy's Growth Plans: NextEra Energy raised its quarterly dividend by 10% to about 62 cents per share and plans for 10% annual dividend growth through 2026, with ambitions to add 30 gigawatts of new generation capacity by 2035, showcasing its commitment to renewable energy.
- Abbott Laboratories' Sustained Growth: Abbott announced a 6.8% dividend increase to 63 cents per share in December, achieving 54 consecutive years of growth, and despite missing fourth-quarter revenue expectations, its dividend growth of over 70% reflects strong profitability and market confidence.
See More
Following Grail's Study Setback, What Remains for Cancer Blood Screening?
- Stock Performance: Grail's stock experienced a significant decline, losing half of its value last Friday.
- Market Reaction: The drastic drop in stock price indicates a negative market reaction, potentially affecting investor confidence.
See More
VivaVision Races for Hong Kong IPO to Sustain Cash Flow
- Clinical Trial Progress: VivaVision's two drugs have reached Phase Three clinical trials, with one receiving regulatory fast track designation as a breakthrough therapy for eye inflammation, indicating its potential in the ophthalmic treatment sector.
- Increasing Financial Pressure: As of September 2025, the company had only 35.77 million yuan ($5.2 million) in cash, while net losses for the first three quarters of 2025 reached 131 million yuan, averaging about 43.33 million yuan per quarter, compelling the company to list quickly to replenish its funds.
- Funding History: Over its funding rounds, VivaVision has raised approximately 735 million yuan, with its valuation soaring from 17 million yuan to nearly 1.83 billion yuan, reflecting investor confidence in its long-term potential for innovative eye care solutions.
- Intense Market Competition: Despite advancements in eye inflammation treatment, the dry eye therapy market is highly competitive, with five innovative drugs already approved in China and another ten candidates at Phase Two or beyond, posing significant commercialization challenges.
See More
IWB Stock 52-Week High-Low Analysis
- Price Range Analysis: IWB's stock has a 52-week low of $264.17 and a high of $382.34, with the latest trade at $376.14, indicating stability near its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing significant inflows or outflows, allowing investors to evaluate the impact on underlying assets and make informed investment decisions.
See More
Abbott's Phased Retirement Program Gains Popularity
- Growth of Phased Retirement: According to a survey by the Society for Human Resource Management, only 7% of firms offer formal phased retirement programs, yet a growing number of workers are seeking flexible work arrangements to transition gradually into retirement, reflecting their desire for better work-life balance.
- Abbott's 'Freedom to Work' Program: Abbott offers its 'Freedom to Work' program for employees aged 55 and older with over 10 years of service, allowing them to work four days a week or take up to five additional weeks off, which, despite a salary reduction, retains full-time benefits and aids in talent retention.
- Rising Retirement Age: Since the launch of Abbott's phased retirement program in 2008, over 2,100 employees have participated, resulting in an increase in the average retirement age from 58 to 61, demonstrating the company's success in knowledge transfer and talent retention.
- Financial Necessity of Employees: Research indicates that one-third of baby boomers are delaying retirement primarily due to financial necessity, with many workers in their 50s and 60s needing to continue working to meet savings goals while maintaining health insurance coverage, highlighting the urgent demand for phased retirement options.
See More
Mead Johnson Faces Major Litigation Challenge
- Litigation Timeline: Mead Johnson's Enfamil product is facing a bellwether trial in the US Multidistrict Litigation set for July 6, 2026, involving over 775 lawsuits, indicating a growing legal risk for the company.
- Potential Liabilities: Analysts estimate that the total potential liability from infant formula litigation could range from £400 million to £8 billion, which could significantly impact Mead Johnson's financial health and investor confidence.
- Market Share Concerns: With Mead Johnson and Abbott Laboratories holding approximately 80% of the US infant formula market, the litigation poses a substantial risk to their market positions, potentially affecting sales and brand reputation.
- Corporate Accountability: Attorneys emphasize that this trial will provide families an opportunity to seek justice, highlighting the manufacturers' failure to adequately warn about the risks associated with cow's-milk-based formulas, which may lead to stricter industry regulations on product safety.
See More
Dividend Stocks Surge Amid Market Volatility, Outperforming S&P 500
- Dividend Stocks Performance: In 2026, dividend aristocrats are outperforming the broader market, with the ProShares S&P 500 Dividend Aristocrats ETF up 10% year-to-date compared to less than 1% for the S&P 500, reflecting investors' preference for stable income amid market volatility.
- Coca-Cola Dividend Increase: Coca-Cola announced a 4% increase in its quarterly dividend to 53 cents per share in February, marking its 64th consecutive year of dividend growth, and returned $8.8 billion to shareholders last year, demonstrating strong cash flow and market stability.
- NextEra Energy's Growth Plans: NextEra Energy raised its quarterly dividend by 10% to about 62 cents per share and plans for 10% annual dividend growth through 2026, with ambitions to add 30 gigawatts of new generation capacity by 2035, showcasing its commitment to renewable energy.
- Abbott Laboratories' Sustained Growth: Abbott announced a 6.8% dividend increase to 63 cents per share in December, achieving 54 consecutive years of growth, and despite missing fourth-quarter revenue expectations, its dividend growth of over 70% reflects strong profitability and market confidence.
See More
Following Grail's Study Setback, What Remains for Cancer Blood Screening?
- Stock Performance: Grail's stock experienced a significant decline, losing half of its value last Friday.
- Market Reaction: The drastic drop in stock price indicates a negative market reaction, potentially affecting investor confidence.
See More
VivaVision Races for Hong Kong IPO to Sustain Cash Flow
- Clinical Trial Progress: VivaVision's two drugs have reached Phase Three clinical trials, with one receiving regulatory fast track designation as a breakthrough therapy for eye inflammation, indicating its potential in the ophthalmic treatment sector.
- Increasing Financial Pressure: As of September 2025, the company had only 35.77 million yuan ($5.2 million) in cash, while net losses for the first three quarters of 2025 reached 131 million yuan, averaging about 43.33 million yuan per quarter, compelling the company to list quickly to replenish its funds.
- Funding History: Over its funding rounds, VivaVision has raised approximately 735 million yuan, with its valuation soaring from 17 million yuan to nearly 1.83 billion yuan, reflecting investor confidence in its long-term potential for innovative eye care solutions.
- Intense Market Competition: Despite advancements in eye inflammation treatment, the dry eye therapy market is highly competitive, with five innovative drugs already approved in China and another ten candidates at Phase Two or beyond, posing significant commercialization challenges.
See More
IWB Stock 52-Week High-Low Analysis
- Price Range Analysis: IWB's stock has a 52-week low of $264.17 and a high of $382.34, with the latest trade at $376.14, indicating stability near its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing significant inflows or outflows, allowing investors to evaluate the impact on underlying assets and make informed investment decisions.
See More
